Table 3: Therapeutic effects of Graptopetalum paraguayense (GP) on DMN-induced liver fibrosis in rats via biochemical analysis (2).

Numeric variablep aCategorical variableb
DrugcWeekdDrug × Week1st to 2nd wk3rd to 4th wk5th to 6th wk

Albumin0.12850.38950.2342−0.170.380.83
GPT0.00030.67690.7826−225−360−501
GOT<0.00010.32980.2164−390−816−1355
Bilirubin<0.00010.67280.7539−0.48−0.75−1
AKP<0.00010.61720.1147−303−230−107
LDH<0.00010.01320.0013−63−141−363
Globulin0.13410.0290.0254−0.750.581.65
Triglyceride0.06580.41160.355−78−84−5
AFP0.00310.89920.6289−0.2−0.1−0.1
CHOL0.3240.98470.3248−16.5−3.64.2
BUN0.04440.58960.4293−13.8−13.6−1.6
ACP0.0970.00040.00061.8−0.7−3.6
PT0.02850.72780.9627−2.4−2.5−5.3
PLT0.00080.38790.4526129249476

a: Significant correction is marked in bold at the 0.05 level by two-way ANOVA.
b: AverageDMN + GP-AverageDMN in 1st to 2nd, 3rd to 4th or 5th to 6th week.
c: DMN or DMN + GP treatment groups.
d: 1st to 2nd, 3rd to 4th or 5th to 6th week.